Macy's, Inc. (M)
NYSE: M · Real-Time Price · USD
12.36
-0.27 (-2.14%)
At close: Aug 1, 2025, 4:00 PM
12.30
-0.06 (-0.48%)
After-hours: Aug 1, 2025, 7:54 PM EDT
Augmedix Stock Forecast
Stock Price Forecast
The 8 analysts that cover Augmedix stock have a consensus rating of "Hold" and an average price target of $13.25, which forecasts a 7.20% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $20.
Price Target: $13.25 (+7.20%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Augmedix stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 5 | 6 | 9 | 8 | 8 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 9 | 10 | 11 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $12 → $16 | Hold | Maintains | $12 → $16 | +29.45% | Jul 28, 2025 |
| Citigroup | Citigroup | Hold Maintains $11 → $12 | Hold | Maintains | $11 → $12 | -2.91% | May 29, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $13 → $12 | Hold | Maintains | $13 → $12 | -2.91% | May 29, 2025 |
| Telsey Advisory Group | Telsey Advisory Group | Hold Maintains $15 → $14 | Hold | Maintains | $15 → $14 | +13.27% | May 29, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $14 → $12 | Hold | Maintains | $14 → $12 | -2.91% | May 6, 2025 |
Financial Forecast
Revenue This Year
21.89B
from 23.01B
Decreased by -4.85%
Revenue Next Year
21.29B
from 21.89B
Decreased by -2.75%
EPS This Year
1.80
from 2.07
Decreased by -12.88%
EPS Next Year
1.86
from 1.80
Increased by 3.20%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 23.3B | 23.0B | 22.9B |
| Avg | 21.9B | 21.3B | 20.1B |
| Low | 20.2B | 18.6B | 17.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.1% | 5.1% | 7.5% |
| Avg | -4.8% | -2.7% | -5.6% |
| Low | -12.2% | -15.0% | -19.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.13 | 2.21 | 2.57 | ||
| Avg | 1.80 | 1.86 | 1.91 | ||
| Low | 1.18 | 1.26 | 1.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.0% | 22.3% | 38.2% | ||
| Avg | -12.9% | 3.2% | 2.8% | ||
| Low | -43.2% | -30.1% | -34.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.